WHAT IS CLAIMED IS:

- 1. A method comprising:
- a) obtaining a peptide or protein that selectively binds to prostate cancer tissue:
 - b) attaching an agent to the peptide or protein to form a complex; and
- c) exposing the complex to a sample suspected of containing prostate cancer cells.
- 2. The method of claim 1, further comprising administering the complex to a human subject.
 - 3. The method of claim 1, wherein the sample is a thin section of a tissue.
- 4. The method of claim 1, wherein the peptide or protein is a targeting peptide.
 - 5. The method of claim 1, wherein the peptide or protein is an antibody.
- 6. The method of claim 5, wherein the antibody binds to GRP78, hsp90α or IL-11Rα.
- 7. The method of claim 5, wherein the antibody binds to a peptide comprising at least 3 contiguous amino acids of a sequence selected from any of SEQ ID NO:39 through SEQ ID NO:67.
- 8. The method of claim 5, wherein the antibody binds to an amino acid sequence selected from SEQ ID NO:39.
- 9. The method of claim 5, wherein the antibody binds to an amino acid sequence selected from SEQ ID NO:42.
- 10. The method of claim 5, wherein the antibody binds to an amino acid sequence selected from SEQ ID NO:46.
- 11. The method of claim 1, further comprising detecting prostate cancer cells in said sample.

12. The method of claim 11, further comprising detecting metastatic prostate cancer in bone marrow.

- 13. The method of claim 1, further comprising diagnosing prostate cancer.
- 14. The method of claim 1, further comprising providing a prognosis for an individual with prostate cancer.
- 15. The method of claim 4, wherein the targeting peptide comprises at least three contiguous amino acids of a sequence selected from any of SEQ ID NO:5 through SEQ ID NO:35, SEQ ID NO:37 or SEQ ID NO:83 through SEQ ID NO:129.
- 16. The method of claim 15, wherein the targeting peptide has an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:37, SEQ ID NO:83 or SEQ ID NO:84.
- 17. The method of claim 1, wherein the agent is a therapeutic agent or an imaging agent.
- 18. The method of claim 17, wherein the therapeutic agent is a drug, a chemotherapeutic agent, a radioisotope, a pro-apoptosis agent, an anti-angiogenic agent, a survival factor, an anti-apoptotic agent, an enzyme, a hormone, a hormone antagonist, a cytokine, a cytotoxic agent, a cytocidal agent, a cytostatic agent, a growth factor, a peptide, a protein, an antibiotic, an antibody, a Fab fragment of an antibody, a hormone antagonist, a nucleic acid, an antigen, a virus, a bacteriophage, a bacterium, a liposome, a microparticle, a magnetic bead, a microdevice, a yeast cell, a mammalian cell, a cell or an expression vector.
- 19. The method of claim 18, wherein the pro-aptoptosis agent is selected from the group consisting of gramicidin, magainin, mellitin, defensin, cecropin, (KLAKLAK)₂ (SEQ ID NO:1), (KLAKKLA)₂ (SEQ ID NO:2), (KAAKKAA)₂ (SEQ ID NO:3) and (KLGKKLG)₃ (SEQ ID NO:4).
- 20. The method of claim 19, wherein the pro-apoptosis agent is (KLAKLAK)₂ (SEQ ID NO:1).
- 21. The method of claim 18, wherein the anti-angiogenic agent is selected from the group consisting of thrombospondin, angiostatin5, pigment epithelium-derived

factor, angiotensin, laminin peptides, fibronectin peptides, plasminogen activator inhibitors, tissue metalloproteinase inhibitors, interferons, interleukin 12, platelet factor 4, IP-10, Gro-\(\textit{B}\), thrombospondin, 2-methoxyoestradiol, proliferin-related protein, carboxiamidotriazole, CM101, Marimastat, pentosan polysulphate, angiopoietin 2 (Regeneron), interferon-alpha, herbimycin A, PNU145156E, 16K prolactin fragment, Linomide, thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, Docetaxel, polyamines, a proteasome inhibitor, a kinase inhibitor, a signaling peptide, accutin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 and minocycline.

- 22. The method of claim 18, wherein said cytokine is selected from the group consisting of interleukin 1 (IL-1), IL-2, IL-5, IL-10, IL-11, IL-12, IL-18, interferon-γ (IF-γ), IF-α, IF-β, tumor necrosis factor-α (TNF-α), or GM-CSF (granulocyte macrophage colony stimulating factor).
 - 23. The method of claim 18, further comprising:
 - a) administering the complex to an individual with prostate cancer; and
 - b) treating the prostate cancer.
 - 24. A composition comprising an adeno-associated phage (AAP).
 - 25. The composition of claim 24, wherein the AAP is a gene therapy vector.
- 26. The composition of claim 25, wherein the AAP comprises a nucleic acid encoding a therapeutic protein.
- 27. The composition of claim 26, wherein the nucleic acid encodes a cytotoxic agent, a cytostatic agent, a cytocidal agent, a pro-apoptosis agent, an anti-angiogenic agent, a hormone, a cytokine or an enzyme.
- 28. The composition of claim 27, wherein the nucleic acid encodes thymidine kinase.
- 29. The composition of claim 25, wherein the AAP comprises a nucleic acid encoding a targeting peptide.

30. The composition of claim 29, wherein the nucleic acid encodes an amino acid sequence selected from the group consisting of GFE, HWGF and RGD-4C.

- 31. The composition of claim 29, wherein the nucleic acid encodes at least three contiguous amino acids selected from any of SEQ ID NO:5 through SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:82 through SEQ ID NO:129 or SEQ ID NO:132.
- 32. The composition of claim 31, wherein the nucleic acid encodes at least three contiguous amino acids selected from the group consisting of SEQ ID NO:34, SEQ ID NO:37, SEQ ID NO:83 and SEQ ID NO:84.
- 33. A method of treating a disease state comprising administering a composition comprising an adeno-associated phage to an individual with a disease.
 - 34. The method of claim 33, wherein the disease is prostate cancer.
 - 35. The method of claim 33, wherein the disease is metastatic cancer.
- 36. An isolated peptide of 100 amino acids or less in size, comprising at least 3 contiguous amino acids of a sequence selected from any of SEQ ID NO:83 through SEQ ID NO:129 or SEQ ID NO:132.
- 37. The isolated peptide of claim 36, wherein said peptide is 25 amino acids or less in size.
- 38. The isolated peptide of claim 36, wherein said peptide is 10 amino acids or less in size.
- 39. The isolated peptide of claim 36, wherein said peptide is 7 amino acids or less in size.
- 40. The isolated peptide of claim 36, wherein said peptide comprises at least 5 contiguous amino acids of a sequence selected from any of SEQ ID NO:83 through SEQ ID NO:129 or SEQ ID NO:132.
- 41. The isolated peptide of claim 36, wherein said peptide is attached to a molecule.
- 42. The isolated peptide of claim 41, wherein said molecule is a drug, a chemotherapeutic agent, a radioisotope, a pro-apoptosis agent, an anti-angiogenic agent,

a hormone, a cytokine, a growth factor, a cytotoxic agent, a peptide, a protein, an antibiotic, an antibody, a Fab fragment of an antibody, an imaging agent, survival factor, an anti-apoptotic agent, a hormone antagonist or an antigen.

- 43. The isolated peptide of claim 36, wherein said peptide is attached to a macromolecular complex.
- 44. The isolated peptide of claim 43, wherein said complex is a virus, a bacteriophage, a bacterium, a liposome, a microparticle, a magnetic bead, a yeast cell, a mammalian cell or a cell.
- 45. The isolated peptide of claim 43, wherein said peptide is attached to a eukaryotic expression vector.
- 46. The isolated peptide of claim 45, wherein said vector is a gene therapy vector.
- 47. The method of claim 2, further comprising targeting delivery of said agent to an organ, tissue or cell type in said subject.
 - 48. A method of treating a lipoma comprising:
 - a) obtaining a targeting peptide selective for adipose tissue;
 - b) attaching the peptide to a therapeutic agent to form a complex;
 - c) administering the complex to a subject; and
 - d) treating a lipoma.
- 49. The method of claim 48, wherein the targeting peptide comprises at least three contiguous amino acids of a sequence selected from SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81 or SEQ ID NO:82.
- 50. The method of claim 49, wherein the targeting peptide has the amino acid sequence of SEQ ID NO:77, SEQ ID NO:81 or SEQ ID NO:82.
 - 51. A method comprising:
- a) obtaining a peptide or protein that selectively binds to ovarian cancer tissue;

b) attaching an agent to the peptide or protein to form a complex; and

- c) exposing the complex to a sample suspected of containing ovarian cancer cells.
- 52. The method of claim 51, further comprising administering the complex to a human subject.
 - 53. The method of claim 51, wherein the sample is a thin section of a tissue.
 - 54. The method of claim 51, wherein the peptide or protein is an antibody.
- 55. The method of claim 51, wherein the antibody binds to a peptide with a sequence comprising at least 3 contiguous amino acids selected from SEQ ID NO:132.
- 56. The method of claim 6, further comprising categorizing a prostate cancer as androgen-dependent or androgen-independent.
- 57. The method of claim 56, wherein said categorizing is based on the expression of IL-11Ra in the blood vessels of said prostate cancer.